Andersen Steen, Jacobsen Peter, Tarnow Lise, Rossing Peter, Juhl Tina R, Parving Hans-Henrik
Steno Diabetes Center, Niels Steensensvej 2, DK-2820 Gentofte, Denmark.
Nephrol Dial Transplant. 2003 Feb;18(2):293-7. doi: 10.1093/ndt/18.2.293.
Blockade of the renin-angiotensin system is the primary target in the treatment of diabetic kidney disease. Angiotensin II subtype 1 (AT1) receptor antagonists reduce albuminuria and lower blood pressure, but the initial time course of these effects after initiation of treatment is unknown. We evaluated the time course of the antihypertensive and antialbuminuric effect after initiation of AT1 receptor blockade by losartan in diabetic nephropathy.
Ten hypertensive type 1 diabetic patients with diabetic nephropathy were included in the study. After a washout period of 4 weeks, patients received losartan 100 mg once daily for 28 days. Every morning, one urine sample was collected for daily determination of albumin/creatinine ratio. Twenty-four hour blood pressure (Takeda TM2420), plasma renin and plasma creatinine were measured at baseline and days 7, 14 and 28.
Baseline levels of urinary albumin/creatinine ratio and 24 h mean arterial blood pressure were 676 (402-1136) mg/g (geometric mean and 95% CI, respectively) and 100+/-3 mmHg (mean +/- SEM). Albumin/creatinine ratio was significantly reduced after 7 days of treatment by 29% (15-41) (95% CI) without significant further reductions during the 28 day study period (P<0.01 vs baseline). Mean arterial blood pressure was significantly lowered by 7 mmHg after 7 days of treatment and remained unchanged throughout the study (P<0.01 vs baseline). Plasma renin was significantly increased from baseline after initiation of losartan treatment and stabilized after 7 days (P<0.01). We found no changes in plasma creatinine during the study.
The initial time course of the reduction in arterial blood pressure and albuminuria are concordant, which suggests that systemic and renal haemodynamic mechanisms are of primary importance in the reduction of albuminuria.
肾素 - 血管紧张素系统阻断是糖尿病肾病治疗的主要靶点。血管紧张素II 1型(AT1)受体拮抗剂可减少蛋白尿并降低血压,但治疗开始后这些效应的初始时间进程尚不清楚。我们评估了氯沙坦起始AT1受体阻断治疗糖尿病肾病后降压和抗蛋白尿效应的时间进程。
10例患有糖尿病肾病的高血压1型糖尿病患者纳入本研究。经过4周的洗脱期后,患者每天服用100mg氯沙坦,共28天。每天早晨收集一份尿液样本用于每日测定白蛋白/肌酐比值。在基线、第7天、第14天和第28天测量24小时血压(武田TM2420)、血浆肾素和血浆肌酐。
尿白蛋白/肌酐比值和24小时平均动脉血压的基线水平分别为676(402 - 1136)mg/g(几何平均数和95%CI)和100±3 mmHg(平均值±标准误)。治疗7天后白蛋白/肌酐比值显著降低29%(15 - 41)(95%CI),在28天研究期间无进一步显著降低(与基线相比P<0.01)。治疗7天后平均动脉血压显著降低7 mmHg,且在整个研究期间保持不变(与基线相比P<0.01)。氯沙坦治疗开始后血浆肾素从基线显著升高,并在7天后稳定(P<0.01)。我们在研究期间未发现血浆肌酐有变化。
动脉血压降低和蛋白尿减少的初始时间进程是一致的,这表明全身和肾脏血流动力学机制在蛋白尿减少中起主要作用。